June 6, 2016
IntegriChain Launches Revenue Analytics Suite for First Unified Revenue Stream View to Analyze 340B Program Abuse and Trends Affecting the Patient Journey
New Suite of Enriched Channel Data Analytics for Life Sciences Manufacturers Identifies Sources of Margin Erosion and Trends in Patient Access
Philadelphia, PA, June 6, 2016 – IntegriChain, a rapidly growing healthcare technology company focused on channel management for life sciences suppliers, today announced the launch of Revenue Analytics, a suite of enriched channel data offering a unified view of commercial and 340B transactions across all covered entities, sites of care, owned pharmacies, and contract pharmacies. Revenue Analytics allow life sciences manufacturers to minimize revenue leakage and margin erosion resulting from 340B program abuse, orphan drug violations, and missing reverse chargebacks as well as offer trend analytics to understand how patients access products.
“Today’s healthcare ecosystem is increasingly complex with the massive expansion of 340B purchasing under the Affordable Care Act and potential missing returns exposing visibility gaps in traditional channel datasets, which is especially critical for new innovative therapies,” said Josh Halpern, co-founder and Executive Vice President of IntegriChain. “For the first time, life sciences manufacturers will have a unified, granular, and authoritative view of commercial and 340B transactions, enabling Finance and Compliance teams to ensure data accuracy and detect abuse and audit targets for 340B transactions and missing chargebacks. Additionally, Sales and Marketing teams will be able to visualize 340B sales growth and channel mix changes to analyze trends, develop more meaningful forecasts, and deep-dive into the analytics and trends for individual sites to improve the patient journey.”
About Revenue Analytics
IntegriChain Revenue Analytics offer enriched datasets that leverage IntegriChain’s best-in-class channel master data and analytics to deliver an unparalleled unified view of how patients access products.
IntegriChain 340B National Analytics deliver a unified view of 340B and commercial transactions by distributor for 340B trending and forecasting and for abuse and audit detection and targeting.
IntegriChain 340B Subnational Analytics offer a unified view and visualizations for 340B and commercial transactions by covered entities, sites of care, owned pharmacies, and contract pharmacies to trend units (including orphan drug usage), sales mix, and returns by individual site.
IntegriChain Chargeback Analytics provide a vital validation tool for preventing future losses due to missing reverse chargebacks by delivering verification of wholesaler-submitted reversals for all returns in 867 data.
Revenue Analytics can be purchased as a full suite or as individual enriched datasets.
IntegriChain is a rapidly growing healthcare technology company, offering the leading cloud for channel data aggregation, analytics, and application for life sciences suppliers to improve patient access. Pharmaceutical, biopharm/specialty pharma, generics, and medtech suppliers leverage insights from IntegriChain’s unmatched visibility to product distribution and demand to optimize product commercialization and to address critical risks throughout the patient journey and product life cycle. IntegriChain delivers the data and analytics foundation for more efficient and service-oriented channel models for mature product categories as well as for innovative products that must balance significant therapeutic benefit with out-of-pocket costs and benefit hurdles. Today IntegriChain is the trusted partner for 13 of the top-15 life science companies and more than 50 other suppliers, totaling $200 billion in annual US commerce. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. For more information, visit www.integrichain.com and our blog, and follow us on Twitter @IntegriChain and LinkedIn.
IntegriChain is a registered trademark of IntegriChain Incorporated. All other trademarks are property of their respective owners.
Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com